The opportunity ahead for Phlexglobal is significant, and I look forward to accelerating the company’s growth trajectory and market leadership.”
-John McNeill, CEO Phlexglobal

Amersham, UK; Malvern, PA. — January 14, 2019 — Phlexglobal today announced that its Board of Directors has appointed John McNeill as Chief Executive Officer and member of the Board of Directors effective January 14, 2019. McNeill previously held the position of President at Sparta Systems, Inc.
“John McNeill is ideally placed to lead Phlexglobal”, said Rick Riegel. “John is a proven life sciences industry veteran with demonstrated leadership, customer focus, product understanding and results. His vision for success will greatly benefit Phlexglobal as the company enters its next stage of further innovation and growth.” In addition to the appointment of John McNeill as CEO, Phlexglobal also announced that Rick Riegel has moved to the position of Vice-Chairman.
Prior to joining Phlexglobal, McNeill was a key member of the executive team at Sparta Systems for 7 years, helping to build out Sparta’s market leading and global solution for quality management systems for the life sciences and other regulated industries. During his tenure, Sparta increased market share and successfully transitioned to a cloud-based SaaS business model. Prior to Sparta, John held leadership positions at IRI, BravoSolution, and VerticalNet.
Building the Right TMF Team for Inspection Readiness, Scalability and Growth As clinical trials become more complex, many Sponsors and CROs find themselves asking the same question: Do we need more
Why portfolio-level TMF oversight is becoming a necessity, not a luxury. The Problem With Thinking Study-by-Study Clinical trials do not happen in isolation. Sponsors and CROs are running multiple
How Senior TMF Study Owners bridge strategy, mentoring and operational delivery. What does it really mean to have an expert in your corner when it comes to your Trial Master File? For organisations
UK: +44 (0) 1494 720420
US: +1 (484) 324-7921
Poland: +48 81 45 46 132